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Abstract
Anemia is a frequent incident for patients with systemic lupus erythematosus (SLE), its 
incidence being reported as 18–80%. Anemia of chronic disease (ACD) is the most common 
hematological syndrome in the evolutionary context of SLE. In anemia of the chronic dis-
ease, cytokines stimulate the production of hepcidin, an acute phase protein, which destroys 
ferroportin produced by hepatocytes. As a result, Fe (iron) is not able to come out from the 
erythrocytes and macrophages and is trapped within them. Anemias from chronic disease 
are usually hypoproliferative processes. This chapter reviews the correlation between sys-
temic lupus erythematosus and anemia of chronic disease in general (but iron-deficiency 
anemia in particular). This text reviews different important methods of examination used to 
diagnose the pathological process of lupus as an immune disease and of the hematopoietic 
system some of these methods include (general blood analysis, Coombs test, serum iron, 
hematocrit etc.). Furthermore, it will discuss the physiopathological mechanism of anemic 
syndrome in systemic lupus erythematosus and the changes of the immune system. In 
conclusion, the relevance of anemia (independent of its cause) is estimated as being both a 
short-term activity of the disease and long-term prognostic factor for the evolution of SLE.
Keywords: anemia, systemic lupus erythematosus, hematological implications
1. Introduction
In general population, anemia is associated with high morbidity in different clinical conditions. 
For example, high prenatal risk, developmental anomalies in children, changes in immuno-
logical status, high risk of infections and pattern of hormonal and metabolic development are 
usually associated with anemia. Anemia is an independent risk factor for the development of 
cardiovascular complications in general population [1–3].
Anemia is present in approximately half of the people with active lupus. Common forms of ane-
mia in these patients are anemia of chronic disease (ACD), followed by iron-deficiency anemia, 
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autoimmune hemolytic anemia, anemia of chronic kidney disease and drug induced. Other 
types of anemia, such as pure red cell aplasia (PRCA), myelofibrosis, B12-deficiency anemia, 
sideroblastic anemia, hemophagocytic syndrome and thrombotic microangiopathy, are rare 
forms described in lupus. Anemias from chronic disease are usually hypoproliferative processes 
[4, 5]. Recent studies have revealed that resistance to erythropoietin (EPO) in systemic lupus 
erythematosus (SLE) can be attributed to antibodies against erythropoietin (anti-erythropoie-
tin). Reduced production and resistance to erythropoietin in patients with SLE is hypothetically 
associated with anemia of chronic disease (ACD) [6, 7]. Normally, red cells live only 120 days 
(approximately 4 months) and they constantly have to be produced by the bone marrow. The 
most common explanation of anemia is the production of fewer red blood cells than usual. 
This can be caused by an inflammation, kidney problems (when kidneys produce insufficient 
hormone, erythropoietin stimulates the bone marrow to produce more red blood cells), iron 
deficiency (without iron, hemoglobin cannot be produced—iron deficiency can be caused by 
excessive menstrual hemorrhage or intestinal hemorrhage caused by non-steroidal anti-inflam-
matory drugs, such as ibuprofen and aspirin) or diminished bone marrow caused by drugs like 
azathioprine and cyclophosphamide. Intestinal hemorrhage can be evident if the stool is dark 
and tarry, but sometimes the hemorrhage is very little and additional analysis are needed for 
the detection of the hemorrhage [3, 4, 8]. Anemia can be caused by the premature destruction 
of red blood cells, named hemolytic anemia, or by simple hemolysis. Sometimes patients with 
hemolysis have paler skin and in these situations the yellowish color of the skin and eyes is not a 
sign of liver problems. Hemolysis is often caused by specific antibodies of the disease that attach 
to erythrocytes. When it is accompanied by thrombocytopenia, it causes thrombotic thrombocy-
topenic purpura. Thrombocytopenia is found in 30–50% patients, and it is caused by antiplatelet 
antibodies or antiphospholipid antibodies. Both can cause severe thrombocytopenia (<50,000). 
Platelet transfusion is generally contraindicated in SLE because of the possibility that the patient 
is exposed to new antigens [5, 9].
Being essential for organ function, a large amount of iron is stored in any organism. Excretion 
of iron from the body is a very slow process, which occurs through epithelial desquamation and 
intestinal secretion.
Anemia of chronic disease is the most common hematological syndrome seen in the evolutionary 
context of SLE. In anemia of chronic disease, cytokines stimulate the production of hepcidin – a 
protein of the acute phase response, which destroys ferroportin produced by hepatocytes. As a 
result, iron is unable to be transported out of the erythrocytes and macrophages. Under the influ-
ence of hepcidin, iron is trapped [7, 10]. In this condition, in spite of sufficient amount of iron in 
the body, bone marrow suffers from insufficiency of iron.
Formation of erythrocytes is affected and their duration of life decreases. Erythrocytes are 
produced in the bone marrow under the influence of erythropoietin, but in anemia of chronic 
disease the cytokines inhibit the production of erythropoietin.
Anemia in patients with SLE is a common manifestation which can result from many causes 
such as changes in the immune system, followed by the activation of cytokines, digestive tract 
bleeding because of chronic consumption of glucocorticoids, various drugs (for example aspirin 
and ibuprofen), presence of enzyme deficiency that predisposes the fragility of RBCs, poor diet 
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and malabsorption syndrome. Sometimes SLE patients might have multiple etiological factors 
for their anemia. For that reason, it is important to establish a complete and correct diagnosis, 
taking into account different therapeutic means [5, 11].
Anemia of chronic disease is determined by a functional deficit of iron, which can be charac-
terized by:
• hyposideremia, despite the adequate/increased amount of iron (increased ferritin in serum);
• direct suppression of erythropoiesis;
• determining the capture of the iron in macrophages;
• limiting the amount of transferrin iron necessary for erythropoiesis makes anemia mild 
and asymptomatic, making it morphologically normocytic/microcytic and saturation of 
transferrin low, suggesting the deficit of iron.
Hemoglobin is the protein present in the red blood cells that transports oxygen from lungs to 
other tissues of the body. Fatigue is a common symptom of lupus and also the first and most 
common symptom in anemia [12, 13]. Anemia can be measured and followed up in various 
ways, including calculation of the red blood cells, which emphasizes a reduced number of RBC, 
a low level of hemoglobin and hematocrit [12, 14].
The diagnosis of a real deficit of iron in a patient with chronic disease can be very difficult to 
determine because chronic diseases can give false-positive results for hyposideremia despite 
the presence of stored iron and can also give false-positive results for higher ferritin level in 
serum, even in the absence of stored iron—the most useful diagnostic test is the soluble trans-
ferrin receptor (STfR)/ferritin level. Soluble transferrin level (STfR) and ferritin change in oppo-
site directions during iron deficiency; this value is extremely sensible for the metabolism of 
iron and can differentiate anemia from chronic disease with the real iron deficit, even if this is 
accompanied by a chronic disease. This value is not useful in the presence of renal dysfunction 
or hemodialysis, when the saturation of transferrin is <20% and ferritin <100 μg/l shows the 
necessity of treatment with iron [2, 14, 15].
2. Physiopathological mechanisms of anemic syndrome in systemic 
lupus erythematosus
Anemia of chronic disease, the most frequent comorbidity in patients with SLE is normo-
chromic normocytic, mild (Hb < 9.5 g/dl) or moderate form (Hb < 8 g/dl) of hyporegenera-
tive anemia. In its physiopathology, cytokines and SLE cells change the homeostasis of iron; 
abnormal erythropoietin (EPO) production, inadequate response to the secretion of eryth-
ropoietin causes erythroid progenitor abnormalities in the cells and diminished life span of 
erythrocytes; these are caused by direct toxic effect on progenitors by formation of free radi-
cals like nitric oxide (NO) and superoxide anion (O2) [16–18].
Changes in the immune system determine the activation of T lymphocytes (CD3+) and mono-
cytes, followed by the production of cytokines such as interleukin-1 (IL-1), interleukin-6 
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(IL-6), interleukin-10 (IL-10), tumor necrosis factor alpha (TNFα) and interferon-gamma (IFN-
gamma), which stimulate the storage of iron in macrophages and synthesis of ferritin (FT), 
which causes decreased availability of iron for erythropoiesis. IFN-gamma, TNFα and IL-1 
have inhibitory effect on the proliferation and differentiation of erythroid progenitors. TNFα 
and IFN-gamma inhibit the production of erythropoietin in kidney. IL-6 and IL-1 (respon-
sible especially for systemic manifestations in SLE, including anemia) were the first cyto-
kines discovered, implicated in stimulating the secretion of hepatic hepcidin. These cytokines, 
being the essential elements in the anemia pathogeny of patients with multiple myeloma, 
acting either independently or through producing hepcidin [10, 17]. Hepcidin represents the 
link between these two essential mechanisms (immunologic and homeostatic dysfunction) 
involved in the pathogenicity of ACD.
In conclusion, not all the causes of anemia in the chronic disease SLE are well known. The 
most characteristic types of anemia are iron-deficiency anemia, autoimmune hemolytic ane-
mia, anemia from chronic kidney failure, vitamin B12-deficiency anemia and other forms. 
The disease is most frequent in women, does not have a well-known cause and has a special 
association with some genes of the immune response. Some affected systems are represented 
by central and peripheral nervous system, lungs, heart, kidneys, serous and other elements of 
the blood. Other systems of the body may also be affected, infrequently. Some other forms of 
anemia found in lupus disease are as follows.
2.1. Autoimmune hemolytic anemia (AHA)
• AHA is a rare phenomenon in patients with lupus. Hemolytic anemia may be classified into 
two major groups: with antibodies at cold and hot temperatures. AHA with hot antibodies 
is mediated by IgG antibodies that can interact with antigens only at 37°C, and the reaction 
with cold antibodies can be as low as 4°C. Coomb test is directly positive and involves one 
of the following elements that interact with the surface of the erythrocytes such as IgG.
• Other hematological disorders such as neutropenia is a common abnormality that ampli-
fies the risk of secondary infections in patients with SLE, but can also be an index of the 
disease state. In addition to neutropenia, lymphopenia is also reported to be a frequently 
seen hematological disorder in patients with lupus [4, 9].
2.2. Leucopenia
It is a hematological disturbance that occurs in half of the patients with SLE, circulating gran-
ulocytes being decreased because of granulocytopenia by destruction in the peripheral circu-
lation (antigranulocyte antibodies, hypersplenism), bone marrow dysfunction, drug-induced 
cytopenia (azathioprine), lymphocytopenia through non-immunological mechanisms (drug 
induced), immunological mechanisms (antilymphocyte-dependent antibodies IgM) and 
nonspecific antibodies, which interact with lymphocytes. Leucopenia appears in over 50% 
of patients with SLE and is associated with granulocytopenia or lymphopenia. Most of the 
times leucopenia can be reversible with adequate immunosuppressive therapy [7, 17, 19]. 
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Often, leucopenia can be a good gravity index regarding the disease activity, and it can also 
appear as a response to the cytotoxic therapy. Leucopenia and neutropenia are the findings 
often present in active lupus, but rarely reach such a low level to cause the infections.
The number of cells can be decreased by azathioprine, cyclophosphamide and other drugs. 
Thus, the number of white cells should always be monitored during the treatment of SLE. If 
the number of white cells decreases too much, lowering the doses of the drugs or discontinua-
tion of the treatment should be done. Dysfunction of the immune system, which causes wide-
spread infection in SLE, is not reflected in the usual blood tests [11, 12, 19, 20].
2.3. Thrombocytopenia
Mild thrombocytopenia (number of thrombocytes 100,000–150,000/μL) is present in 25–50% 
of patients with SLE and those with less than 50,000/μL appears to be only 10%. The most 
common cause of thrombocytopenia in SLE is the autodestruction of thrombocytes.
Impaired production of thrombocytes is drug induced (as a result of bone marrow suppression). 
The main underlying mechanism of this event is the binding between immunoglobulin and 
thrombocyte after the destruction in spleen, almost similar to idiopathic thrombocytopenic pur-
pura. Antibodies against thrombocytopenic purpura were detected in the serum of patients with 
SLE and correlated with thrombocytopenia [10, 13, 21].
Idiopathic thrombocytopenic purpura can be the first sign in SLE, followed by other symptoms 
that can appear later. In these cases, the presence of high antinuclear factor (ANAs) titer of nuclear 
antigen increases the possibility of having SLE. A detailed clinical and laboratory examination in 
many of these cases may reveal the supplementary index of SLE. Patients with lupus suffer fre-
quently from osteoporosis, because they sum up the risk of predominant feminine population 
and long-term corticosteroid therapy [3, 14].
Specific antibodies for coagulation factors are seen in SLE, which is frequently associated with 
bleeding. These antibodies are usually present against II, VIII, IX, XI or XII factors. This abnor-
mality is accompanied by hypercoagulation and not by major bleedings. The blood of a SLE 
patient can be hypercoagulable for various reasons other than procoagulant antibodies; these 
include inherited deficiency of C, S factors or IIIrd antithrombin. Urinary loss of antithrombin 
III in patients with nephrotic syndrome also leads to a hypercoagulability state.
3. Methods of investigation
The laboratory examination has particular importance in the diagnosis of the pathologi-
cal processes of lupus as an immune disease and of the hematopoietic system. Ideally, a 
peripheral blood analysis is done that includes all the disease manifestation by the quan-
tity and quality index, for example morphological characteristic of erythrocytes, leukocyte, 
morphological modifications of leukocytes and the presence of the pathological cells. These 
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values provide significant data for establishing the diagnosis for hematological maladies. 
Investigations of the number of reticulocytes and thrombocytes also have an important role 
in the diagnosis [1].
General blood analysis. Its purpose is to calculate the number of erythrocytes and leukocyte. 
Evaluation of the hemoglobin level, erythrocytes and hematocrit index is done for confirmation 
of anemia. A complete hemogram is performed to evaluate the global hematopoietic system 
and the presence of inflammation. A particular importance is given to the morphological study 
of erythrocytes from the blood smear, diameter and the form of erythrocytes (by anisocytosis 
and poikilocytosis mark) [2, 22].
Hemoglobin is a tetrameric molecule and contains iron with porphyrin structure. Iron is capable 
of reversible link with oxygen only in ferric phase. Iron oxidation in its ferric phase determines 
the methemoglobin formation, which alters the absorption and determines the brownish blood 
coloration. Normal limits of hemoglobin is 120–140 g/l for women.
The majority of authors distinguish three grades of anemia: grade I—the content of hemoglobin 
varies from 91 to 110 g/l, grade II—hemoglobin values vary from 71 to 90 g/l and grade III—the 
level of hemoglobin fluctuates from 51 to 70 g/l [1, 17].
Erythrocytes. The number of erythrocytes represents the main test for evaluation of eryth-
ropoiesis. Erythrocytes are investigated by measuring the concentration of hemoglobin and 
hematocrit; based on the values of erythrocyte index: medium erythrocyte volume (MEV), 
mean corpuscular hemoglobin concentration (MCHC) and mean quantity of hemoglobin in 
erythrocyte (MCH) are calculated by the analyzer. All these values characterized erythrocytic 
population qualitatively.
Number of erythrocytes as a single parameter has insignificant diagnostic value, so that the 
correct evaluation of erythrocyte mass is done through the correlation with hematocrit.
Hematocrit is the volume percentage (vol%) of red blood cells in blood. It is normally 45% for 
men and 40% for women. It is considered an integral part of a person’s complete blood count 
results, along with hemoglobin concentration, white blood cell count and platelet count. The 
hematocrit with erythrocytic index is used in the diagnosis of diverse types of anemia [3, 4].
Serum iron is determined using colorimetric method and helps in the diagnosis of iron defi-
ciency. Serum iron is a medical laboratory test that measures the amount of circulating iron that 
is bound to transferrin. Clinicians carry out this laboratory test when they are concerned about 
iron deficiency, which can cause anemia and other problems. About 65% of the iron in the body 
is bound up in hemoglobin molecules in red blood cells. About 4% is bound up in myoglobin 
molecules. Around 30% of the iron in the body is stored as ferritin or hemosiderin in the spleen, 
the bone marrow and the liver. Small amounts of iron can be found in other molecules in cells 
throughout the body. None of this iron is directly measurable from serum level.
However, some iron circulate in the serum. Transferrin is a molecule produced by the liver 
that binds one or two iron ions, i.e. ferric iron, Fe3+; transferrin is essential if stored iron is to be 
moved and used. Most of the time, about 30% of the available sites on the transferrin molecule 
are occupied. The test for serum iron measures the iron molecules that are bound to transferrin 
Current Topics in Anemia170
and circulating in the blood. The extent at which transferrin molecules are occupied by iron 
ions can be another helpful clinical indicator, known as percent transferrin saturation. These 
tests are generally done at the same time. Considering the laboratory results together is an 
important part of the diagnostic process for conditions such as anemia, iron-deficiency anemia, 
anemia of chronic disease and hemochromatosis.
It is extremely important to collect the blood correctly for determining the serum iron. It was 
noted that the tubes washed with distilled water contained traces of iron. Another important 
matter to be considered is that the patient should not get any iron medication at least 5 days 
before analysis [8, 23].
Ferritin content in serum facilitates the diagnosis of iron deficiency in pre-latent period. 
Ferritin is the diagnostic marker in iron deficiency, and the latex-test method is validated for 
the evaluation of iron storage. Ferritin is measured in the serum using polyclonal antibodies 
for ferritin absorbed by the latex particles. The established norm is 10.00–160.00 g/l. Values 
under 10.00 g/l are considered low.
Erythropoietin (EPO), a glycoprotein hormone secreted by the kidney in the adult and by 
the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell 
production (erythropoiesis). The Biometrica EPO ELISA test is a immunofermentative in vivo 
diagnostic test, which determines the quantity of serum erythropoietin. The glycoprotein hor-
mone erythropoietin (EPO) is an essential growth and survival factor for erythroid progeni-
tor cells, and the rate of red blood cell production is normally determined by the serum EPO 
concentration. EPO production is inversely related to oxygen availability, so that an effective 
feedback loop is established, which controls erythropoiesis. Since recombinant EPO became 
available as an effective therapeutic agent, significant progress has also been made in under-
standing the basis of this feedback control. The main determinant of EPO synthesis is the tran-
scriptional activity of its gene in liver and kidneys, which is related to local oxygen tensions. 
This control is achieved by hypoxia-inducible transcription factors (HIF), consisting of a con-
stitutive beta-subunit and one of two alternative oxygen-regulated HIF alpha subunits (HIF-
1alpha and HIF-2alpha). In the presence of oxygen (normoxia), the HIF alpha subunits are 
hydroxylated, which targets them for proteasomal degradation. Under hypoxia, because of the 
lack of oxygen molecule, HIF cannot be hydroxylated and is thereby stabilized. Although HIF-
1alpha was the first transcription factor identified through its ability to bind to an enhancer 
sequence of the EPO gene, more recent evidence suggests that HIF-2alpha is responsible for 
the regulation of EPO. Although EPO is a prime example for an oxygen-regulated gene, the 
role of the HIF system goes far beyond the regulation of EPO, because it operates widely 
in almost all cells and controls a broad transcriptional response to hypoxia, including genes 
involved in cell metabolism, angiogenesis and vascular tone. Further evidence suggests that 
apart from its effect as an erythropoietic hormone, EPO acts as a paracrine, tissue-protective 
protein in the brain and possibly also in other organs [11].
Coombs test. Circulatory anti-erythrocyte antibodies are detected using indirect Coombs test. 
Unlike direct Coombs test that uses patient’s erythrocytes, indirect test uses serum. At the 
second phase, this mixture is supplemented with a solution that contains human antiglobulin 
antibodies. If antibodies exist in the patient’s serum, agglutination appears.
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Thrombocytes. Normal thrombocytes are represented as small cytoplasmic fragments, light 
blue colored, with azurophilic diffuse small grains (red-purple), with a diameter of 2–4 μm and 
oval in shape. The number of thrombocytes can be estimated in the analyzer or in the smear. 
The normal value of thrombocytes is 180.0–320.0∙10/l, and the values under 180 thousand are 
considered as decreased—thrombocytopenia.
Leukocytes—the white cells from the plasma. Depending on the function and their role, 
leukocytes are divided in five categories: basophil, eosinophils, lymphocytes, monocytes and 
neutrophils. Normal values of leukocytes are 4.0–9.0∙10/l.
ESR (Westergren)—Erythrocyte sedimentation rate is the rate at which the red blood cells 
make sediment during 1, 2 hours or 15 minutes.
ESR is regulated by the equilibrium between pro-sedimentary factors, main being fibrinogen, 
and the negative charge of erythrocytes. The Westergren method is the most frequent method 
used to determine the erythrocyte sedimentation rate.
The ESR is a simple nonspecific screening test that indirectly measures the presence of inflam-
mation in the body. It reflects the tendency of red blood cells to settle more rapidly in the face 
of some disease states, usually because of increases in plasma fibrinogen, immunoglobulins 
and other acute-phase reaction proteins. Changes in red cell shape or numbers may also affect 
the ESR.
There are two main methods used to measure the ESR: the Westergren method and the 
Wintrobe Method. Each method produces slightly different results. Most laboratories use the 
Westergren method.
4. Methods and results
Through analyzing the instruments used for evaluating the SLE activity, we chose the Systemic 
Lupus Activity Measure (SLAM) index that reflects the clinical and laboratory parameters of 
SLE. The score of this instrument varies between 0 and 20 points, being considered prefer-
able as compared to Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), for 
the appreciation of anemia in context with SLE [24]. SLAM is a quantity index that includes 
37 parameters, compared to 10 domains that reflect the state of 8 organs and systems (consti-
tutional, reticuloendothelial, pulmonary, cardiovascular, neuromotor, hematological, ocular 
and articulations) shown by laboratory data. Each domain is marked from 3 to 11 parameters.
We obtained the next distribution: low activity is mentioned till 10 points, medium—10–20 
points and high grade—over 20 points [3].
In accordance with the purpose, a group of 110 patients with systemic lupus erythematosus 
have been selected. About 87 of the investigated patients complied with SLE diagnosis crite-
ria issued by the American College of Rheumatology, which constituted the baseline study 
group. We had only one male patient, so we excluded him from our research to avoid gender 
misrepresentation.
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In our study, we obtained the data about the onset disease age that ranged from 21 to 62 years 
(mean age—32.8 ± 1.32), but more often the disease was established at a young age—between 
21 and 39 years. The mean age of the patients at the time of examination was 41.37 ± 1.4 (21–
65 years), with the onset of the disease at 8.6 years of age. At the moment of examination, 
patients were mostly between 21 and 39 years and only eight were over 50 years old. We were 
also interested in analyzing the duration of the disease—from 1 to 365 months (30 years).
In this study, each patient was evaluated individually. We analyzed the obtained results from 
SLAM compartments—general, clinical and laboratory. In each compartment, we included 
five possible answer variants: 1—absent or normal; 2—easy; 3—moderate and 4—severe. It is 
noted that in SLAM the “not examined patient” heading is included.
Fever has been characterized by the levels scored in the SLAM, and the indices like oral and 
nasal ulcers, alopecia, vasculitis, Raynaud syndrome and anti-DNA antibody-dc had two 
answers Yes or No, which signifies the presence or the absence of them. Other components 
of SLAM score, which refers to the component status, were represented by a hematological 
evaluation of some variables such as leukopenia, thrombocytopenia and lymphopenia; strati-
fication of hemoglobin levels and ESR represents the severity of pathological process.
Skin damage was manifested by the nose or mouth sores, rashes, malar erythema and photo-
sensitivity. The detection of at least one of these conditions adds a clinical score SLAM and it 
is expended to disease activity. Cutaneous manifestations such as maculopapular erythema 
or deep lupus has denoted with 3 points of damage to more than 50% of the body surface 
(ASC), with 2 points to extinction of 20–50% and with only 1 point in case of involvement of 
less than 20% of the area of the manipulation. Similarly, the presence of vasculitis has been 
noted with the respective score summary area involved. Eye manifestations are presented by 
corpuscles, bleeding (retinal or colloid) or episcleritis, papillitis or pseudomotor cerebri, and 
depending on the absence or presence and severity of these events, it produces a score from 0 
to 3 points for each clinical index. The central nervous system is affected frequently in lupus 
patients. The most frequently symptoms were migraine, epilepsy and chorea.
Chronic ulcers, avascular necrosis and hemolytic anemia were observed in our patients with 
a frequency of 17.4, 8.7 and 8.7%, respectively. Our data on the incidence of avascular necro-
sis and chronic ulcers are similar to those shown in the literature, and only for hemolytic 
anemia, the data were lower than the presented percentage of Giannouli [25]. We diagnosed 
a small number of valvulopathy (8.7%). Referring to confirm secondary APS by laboratory 
variables, we found that more often anticardiolipin (ACL) IgG antibodies were found than 
IgM—60.9 vs. 30.4%, which shows that ACL IgG antibodies have sensitivity and high speci-
ficity and can be indicated in the research plan of patients with SLE in order to forecast pos-
sible thrombosis. Analyzing the results described, we concluded that APS was associated 
with SLE in 26.7% of cases, which corresponds to the data reported by Duarte [23]—28% of 
cases, but it differs from some older records invoked by Nossent et al. [7], they detected APS 
in 54% of patients with SLE. Typical signs of antiphospholipid syndrome—thrombosis—
have been developed frequently in 60.9% of patients, including 21.7% of these were recur-
rent. Antiphospholipid syndrome with concomitant thrombosis in the system of more veins 
and/or arteries called APS cascading or Asherson’s syndrome, which endangers the patient’s 
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life or seriously alters the quality of life through complications that may arise. Obstetric 
pathology was associated frequently in 52.2% of cases examined and negatively affected the 
prognosis of the disease. This compromises the possibility of a normal pregnancy; there-
fore, patients with APS associated with SLE can conceive only by an adequate treatment and 
should be under rigorous surveillance.
We came across a patient with the medical history of systemic lupus erythematosus, iron-
deficient anemia and symptoms of antiphospholipid syndrome. From this case, relevance of 
hematological damage in SLE and APS patients has emerged. So, we continued research ana-
lyzing hematologic risk factors that increase individual susceptibility in SLE patients in terms 
of morbidity and mortality through hematologic damage, including autoimmune hemolytic 
anemia. Preventive hematology succeeded to prove undoubtedly that by addressing hemato-
logic risk factors significant reduction of the incidence, prevalence, complications and mortal-
ity from diseases of the hematopoietic system could be reduced.
Less has been disclosed on the overlapped quantitative influence of hematologic risk factors 
in patients with autoimmune inflammatory chronic diseases such as idiopathic inflammatory 
myopathies, Sjogren’s syndrome and SLE, as it admits that the risk factors interact between 
themselves, multiplying the hematological risk, which may impact the patient’s condition 
during the morbid evolution of the disease. For these reasons, we analyzed the morbid hema-
tologic risk factors in two distinct groups by quantifying them, choosing for individuals with 
SLE and healthy people.
At the next stage, we tried to analyze disease activity and organic damage index depending 
on the grade of anemia and the presence of anti-DNA antibodies.
According to our results, high SLAM scores (18.78) were associated with severe anemia with 
Hb level of 51–70 g/l, and they were having organic damage index values of 1.15. In our 
study, the lowest values of the examined indices were demonstrated in the absence of anemia 
(SLAM – 7.17, damage index – 0.56) with a background of negative anti-DNA. In the medium 
and moderate forms of anemia, SLAM score and damage index were moderately elevated.
Analyzing the anticardiolipin antibodies, IgG and IgM, in all these groups, we found that the 
average IgG antibodies was higher in the group of patients with ACD—12 (35%) cases versus 
patients in groups with iron-deficient anemia and AHA, where the indices were 5 (25%) and 
1 (20%) (p > 0.05).
The same frequency was also observed in the level of anticardiolipin IgM antibodies. Patients 
(20 (33.9%)) with iron-deficient anemia and AHA + ARF (anemia of renal failure) had identi-
cal levels of IgM anticardiolipin antibodies in 20% of cases, whereas the ACD patients had a 
higher rate of 26.5%. We noted that the C3 complement level was reduced to over 80% of cases 
of anemia in all groups, a situation that indicates high disease activity.
Analyzing the frequency of high titers of anti-DC DNA, we observed that in groups of patients 
with chronic anemia and iron-deficiency anemia this index was positive in 70% of cases and 
reported in 44 patients as compared to Group III, where DNA anti-DC was positively observed 
only in 2 (40%) patients.
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In the third group of patients, lupus nephritis was detected more frequently in 60% of cases, 
whereas in groups of patients with anemia of chronic disease and iron-deficiency anemia, lupus 
nephritis was detected in 40% of cases. The differences were statistically significant (p < 0.01).
For confirming anemia and the quantification of its intensity, we appealed to the index of the 
disease activity in hematological lupus—Systemic Lupus Activity Measure (SLAM), which is 
a test that measures the activity of the disease in patients with SLE through the condition of 
23 clinical and 7 laboratory parameters commensurate with points. The total possible score 
of this instrument varies between 0 and 20 points. Unlike SLEDAI, the SLAM index includes 
not only objective signs and laboratory parameters but also the evaluation of the hemoglobin 
level and the hematocrit. Analyzing the obtained data, we discovered that of the 59 patients 
with anemia, 34 (57.6%) were diagnosed with anemia of chronic disease and accumulated an 
average of 22.6 ± 1.94 according to the SLAM score, a result that is equal to a high activity of 
the disease; 20 patients (33.9%) with iron-deficiency anemia received 18.9 ± 1.14 score having a 
moderate-high activity of the disease and 5 (8.5%) of the interviewed patients with other types 
of anemia obtained 24.9 ± 1.03, a score qualified as a high activity of the disease.
5. Statistical evaluation of the used methods
Data obtained as a result of investigations were processed by computerized analysis (SPSS), 
correlation and discriminating variation. The degree of correlative relations between the eval-
uated parameters was assessed using the correlation coefficient R.
Conclusive differences between the mean values of the parameters studied in different batches 
were estimated using the Student’s t test.
Comparing the results of the disease estimated by two questionnaires, it has been inferred 
that the SLAM, which was drawn up after multiple multidimensional studies, is based on the 
experience in the field of the assessment of disease activity to patients with lupus, which can 
be validated as a sensitive instrument in measuring lupus activity and for detection of pos-
sible hematological changes in this pathology. The SLAM index is variable, with the instru-
ments and patients included in the study group, and it seems that it has outrun the SLEDAI 
of being informative in measuring lupus activity, the signs and symptoms activation of pre-
existing hematological changes. It should be noted that SLAM evaluates, like the SLEDAI 
does, light organic manifestations, as well as the serious ones, which define the prognosis of 
the disease and the amount of organic damage index.
We were interested to estimate general state of health through SLAM, which is not stipulated 
in the SLEDAI. And that is because a person without neurolupus, but with a poor general 
condition estimated by the SLEDAI may display a low score, and the same patient assessed 
after SLAM can display with proper activity according to the index that is constitutionally 
expended score from hematological changes. We recorded the importance of the accuracy of 
the applied tool according to the hypothesis, the first-ever SLAM is designed to record only 
the symptoms reported by the patient due to SLE, but sometimes it becomes difficult to dis-
tinguish claims of secondary manifestations of light lupus exacerbations.
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In the tests for the evaluation of disease activity in accordance with the questionnaire, in addi-
tion to SLAM, clinical examination has taken into account and some laboratory variables such 
as the number of leucocytes, lymphocytes, platelets, hemoglobin and ESR. Hemoglobin val-
ues ranged between 68 and 148 (107.6 ± 2.1) g/l, they being an indication of anemia. Leukocyte 
index in the batch of examined patients noted in average 1900–8800 (4.38 ± 0.3). The average 
values of lymphocytes were 9942 ± 0.4 (variations between 565 and 1900 or from 12 to 36%), 
and the level of platelets has been downsized considerably—246,900 ± 9.2 (numerical varia-
tions between 111,200 and 450,000).
We analyzed the ESR as important hematological index, which increased the number of 
patients to 64% (74.4% advertising and reflecting the high activity of the disease).
We were interested to analyze the titers fractions C3 and C4 of the complement, along with the 
complement titer, which ranged between 1:4 and 1:128. It is worth noting that complement C3 
fraction joined in the range of 6.8 to 130 mg/dl (23.4 ± 3.4), predominantly being low. C4 fraction 
was found for low and medium (8.22 ± 1.48) with variations between 4.0 and 22.4 mg/dl, the 
most common being dropped in the majority of patients with systemic lupus erythematosus.
We were interested in comparing the results of two cohorts in the SLAM. Patients included in the 
study were divided, as we agreed in two batches: with anemia—59 cases (68.6%) and without 
anemia—27 cases (31.4%).
To analyze anemic syndrome, two groups, which consisted of 59 patients with anemia and 
27 patients without anemia, were numerically different to compare, so later we resorted to 
instrumental indexes included in the scale of assessment of the SLAM disease activity.
Comparing groups through the constitutional component, it was estimated that the patients 
who had various types of anemia, constitutional abnormalities, included in this section, were 
detected more frequently than those without anemia (p < 0.05). We also found that the skin 
of the patients in the first group, with anemia were more frequently affected, compared with 
the group of patients without anemia and fatigability (43.2%) were present in bigger intensity 
was expressed in the batch of patients with anemia. It could define the basic disease, but pre-
cipitated by the presence of anemia.
Collaboration obtained outlined in the following: oral ulcers, periangle erythema and photo-
sensitivity were found in a greater number of patients with anemia—46 (77.9%) in compari-
son with batch without anemia, where they were detected in 18 (66.7%) patients. In addition 
to erythema alopecia and discoid lesions being extended to patients with anemia.
After the estimation of lupus activity on cardiovascular impairment, the results revealed higher 
values in the batch of patients with anemia to 61.0% (versus 29.9% cases), and in the group with-
out anemia, we can summarize that the activity has an impact on disease anemia or maintain 
this pathology. Speaking about the effect of SLE on central nervous system, it was observed 
especially in patients with anemia, accounting for 57.6% of cases having an impact on lupus 
activity. Our data transpose with literature data show that the damage to the nervous system 
reflects the activity of the disease in patients with anemia [3].
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Comparing the values of lymphocytes in both groups of patients, we have revealed that lym-
phocytopenia was more specific in the group of patients with anemia—49.1% of cases had 
decreased lymphocyte levels as low as 565 cells. Thrombocytopenia was also more common 
in patients with the beginning of anemia in lupus. As a matter of fact, the ESR, primarily, is a 
common index, and it was investigated in terms of different rates of acceleration, depending on 
the activity of the disease. Defining line was inspired by the study of LIGHT XXIX (Villa, 2005), 
which divided the ESR values into four categories: <12—normal, 12 to 30—average accelera-
tion, 30 to 50—moderate hike and over 50 mm/hour—marked acceleration, the results being 
calculated after an hour and the possibility of making a finding after 2 hours (to 6–24 mm).
We were interested in analyzing the disease activity and damage rate index of various categories 
of ESR. ESR has been determined to be of average elevation—12 to 30, moderate elevation—30 
to 50 and marked as acceleration—over 50 mm/hour.
We analyzed whether the activity, SLAM index and IL are reflected in ESR. According to the 
data, ESR was independently associated with high scores of SLAM. It was found that accel-
erated ESR associated with both disease activity, as measured by the SLAM, and with high 
scores of the SF-36, which had been in decline. The relation between index variables and effect 
on the quality of life as measured by the SF-36 was foreshadowed.
It should be noted that the increase in ESR was not dependent on the organic damage index. 
We can conclude that the erythrocyte sedimentation speed is a relevant test and can be consid-
ered a sensitive index. ESR has been correlated with disease activity, assessed by SLAM and 
has impact on the quality of life, based on estimates by the SF-36.
6. Risk factors for the development of hematologic manifestations  
in SLE
We took the risk factors as a research vector in order to highlight and analyze their impact later 
on the installation of hematological lupus and their interference with the subsequent devel-
opment of the disease. Data displayed in the recent related literatures highlight both gen-
eral and specific risk factors for hematological lupus. General risk factors are hypertension, 
diabetes, obesity, dyslipidemia, smoking (more than 10 cigarettes per day), valvular heart 
disease and/or atrial fibrillation, cumulative doses of glucocorticosteroids >10 g, oral con-
traceptives, pathology of thyroid (history of hypo- or hyperthyroidism, antithyroid therapy 
or HRT) and family history of psychiatric illness [18]. Specific risk factors involve increased 
levels of antiphospholipid antibodies, the presence of lupus anticoagulant and antiphospho-
lipid syndrome and the presence of Raynaud’s phenomenon, livedo reticularis and cutaneous 
vasculitis [10, 14].
An imperative of assessing anemia is presented by identifying and stratification of the impor-
tance of each clinical and serological parameter suggested as a risk factor for hematopoietic 
system involvement in lupus [13].
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From the study, we observed that the most commonly found index in patients with lupus was 
the antiphospholipid syndrome, which was present both in patients without hematological 
damage—8 (9.3%) cases and in those with severe hematological damage—15 (17.4%) cases. 
Our survey data coincide with those stipulated in researches throughout the world, where 
the association of antiphospholipid syndrome is most often reported anemia pattern in lupus.
According to the following data, the presence of livedo reticularis in patients without anemia 
was detected in 14 (16.3%) cases and in patients with anemia in 17 (19.7%) cases. Thus, we pre-
sume that the presence of livedo reticularis in the study conducted by us is associated with 
hematologic manifestations and can be considered as a risk factor of a hematopoietic system 
involvement in patients with lupus. The newest scientific reports present the Raynaud syn-
drome as a specific risk factor for developing anemia, mainly for ACD (anemia of chronic dis-
ease) and iron-deficient anemia [7, 13]. According to our data, Raynaud syndrome was present 
less—only in 3 (3.5%) patients without anemia and in 6 (6.9%) patients who developed anemia.
Clinical examination of patients noted that cutaneous vasculitis has been associated closely 
with various events in the development of anemia and was present in 12 (13.9%) patients, since 
patients without anemia only in 5 (5.8%) cases.
In addition to specific risk factors, we were concerned about examining generic risk factors that 
were less connected with anemia before. We found a close association between hypertension 
and hematological manifestations—11 (18.6%) patients. It is important to mention that in 2 
(2.3%) cases where diabetes was detected, hematological syndromes were observed simulta-
neously. Following the examination, we reported that factors such as obesity, dyslipidemia, 
smoking excessively and cumulative dose of glucocorticosteroids >10 g were identified mainly 
in patients who developed various hematologic manifestations.
A special role is given to valvulopathy, which was detected in 5 (5.8%) patients without anemia 
and 6 (6.9%) patients with anemia. The studies in the domain show a high frequency of anemia 
in patients with valvulopathy of left heart in systemic lupus erythematosus [20]. Other research 
highlights the frequent association of renal and hematological manifestations in lupus [11, 26]. 
According to data reported, kidney damage was detected in 4 (4.6%) patients without anemia 
and in 24 (27.9%) patients with anemia. The risk profile is complemented by another factor, 
such as compromised neuropsychiatric history detected in 5 (5.8%) patients in the group with 
hematological antidamage (clarify).
Summarizing the exposed view of the risks of the patients with SLE, we can register that 
antiphospholipid syndrome, livedo reticularis, skin vasculitis, smoking, cumulative dose of 
glucocorticosteroids >10 g and kidney damage are more commonly found in the context of a 
hematological lupus than in those without impaired heme.
7. Synthesis of the obtained results
At the current stage, the study of the hematological manifestations in systemic lupus ery-
thematosus (SLE), which is a severe, multisystem autoimmune disease of unknown etiology 
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with varied clinical and paraclinical expressions associated with a hyper production of auto-
antibodies and with a potentially major fatality rate, represents a domain of scientific interest 
and an important medicosocial issue [19].
In the past 5 years, thanks to immunological and morphopathological achievements and the 
usage of techniques of fundamental organic research, important progress was obtained in 
regard to the diagnosis, monitoring and the treatment of autoimmune diseases.
Nevertheless, the diagnosis of this disease [11] and the bearing of the expenses of the social 
support persist because SLE has a major potential of disablement and thereby affects the qual-
ity of life severely. The prevention of relapses transforms into an extension of the remissions 
leading to a mostly regular social inclusion and reduced social costs through limiting the 
hospitalization time [24]. Still, the impact of the pathology of the hematopoietic system on the 
quality of life remains uncertain.
In the presented paper, we intended to analyze the modern research regarding the clinical 
and paraclinical diagnosis of systemic lupus erythematosus. We have examined a group of 
patients with lupus by thoroughly researching the hematopoietic system—a clinical criteria 
discussed in the specialty literature. In the past 10 years, these discussions [12, 13] are related 
not only to the classically iterated clinical manifestations but also to their quantification 
through instruments and also using hematological, immunological and paraclinical methods.
In our study, the female/male ratio was 86 (100%), respectively, 0. Analyzing the average age 
of onset, we have established that the onset of the disease was at various ages—from 21 to 
62 years old (average 32.8 ± 1.32) but essentially young people are affected. At the moment 
of examination, the patients observed were averagely 41.37 ± 1.40 with variation intervals 
21–65 years. The analysis of the disease duration detected significant divergences: from 1 
month up to 365 months (48 years). In the study, we have examined patients with an aver-
age evolution span of the lupus process of 98.28 months (8.6 ± 0.47 years), most frequently 
between 1 month and 5 years. A study of prospective analysis was accomplished by Harly 
(1989) [11] but with an average evolution span of the lupus process of 5.4 months and because 
of the shorter stage, a disparity of results is presumed when it comes to a comparison to our 
own data regarding the cumulative doses of corticosteroids and the index of organ lesion.
Throughout our study, we were interested in distinguishing the etiological aspect of the 
moment of onset of SLE, an aim for which we have intended to reflect the specter of triggers 
through the overlap of anamnestic data that were accurately collected from the patients 
included in the study and divided into two groups: those with anemia and those without 
anemia. Our results revealed the presence of stress in 11.1% of those who did not develop 
anemia and in 10.2% of those who developed hematological syndromes during the disease. 
This determined us to consider that the psychoemotional stress was significantly involved 
in both groups included in the study. Exposure to low temperatures was identified both in 
the evolutionary context of the patients without anemia—18.5% and in that of those with 
anemia—20.3%. Another trigger, antecedents of exposure to sun, was detected in 33.3% 
of lupus patients without subsequent hematological manifestations and in 27.1% of those 
who developed anemia. It seemed that the exposure to sun generated the systemic lupus 
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erythematosus but it somehow was a more protective measure for the following lesion of 
the hematopoietic system while the vaccination was less actively implicated in the onset 
of lupus—in 3.7% but those cases presented with a significant potential of hematopoietic 
system implication in the course of the disease—in 1.7% of cases. Simultaneously, we estab-
lished that 29.6% of the patients without anemia and 32.2% of those with anemia could not 
outline any causes that led to SLE, this leaving room for more elaborate studies on this topic 
in the future.
Thus, the comparative assessment of the conditions which preceded the disease in the study 
groups revealed that the insolation and the exposure to low temperatures take up the biggest 
share as triggers for the development of hematological syndromes in systemic lupus erythe-
matosus, while the psycho-emotional stress and the vaccination are not directly responsible 
for the onset of lupus but their impact on the development of anemia is not excluded.
For the estimation of the activity of lupus, we chose a validated instrument—the SLAM index. 
The results of the investigation confirmed that the use of this index is also practicable in the 
dynamic assessment of the activity of the process and the implication of the hematopoietic 
system rendered through anemia, leukopenia, lymphopenia, thrombocytopenia and acceler-
ated erythrocyte sedimentation rate. Referring to the average score of the SLAM index, it was 
higher in the patients included in the study than in the prospective study presented by Bertoli 
(2007) [24], constituting 22.6 ± 1.94 versus 19.4 ± 5.5. It should be noted that on the position of 
significant discrepancy is the fact that all the patients from our group of study were receiving 
corticosteroids, whereas in the reference study only 69.2% of the patients were receiving corti-
costeroids at the moment of the examination.
The clinical picture of lupus presented very diversely by involving different organs and systems. 
We wanted to compare the frequency of the diagnostic criteria ACR 1997 for SLE met by the 
patients in our group of study and those from the reference study reported by Giannouli (2006) 
[23], where the prevalence of anemia between the lupus patients was 50%. Similar data were 
published by Bertoli (2007) [20]. Considering that we detected a rate of 68.8% of hematopoietic 
system implication in our study, we continued to compare our results with other studies. In this 
connection, we discovered that the results obtained by Voulgares (2000) and Alastair [1] proved 
the hematopoietic system affliction at a rate of 14 and 80%, respectively. It is noteworthy that 
in the longitudinal study LUMINA LI (2007) [24] carried out on a cohort of 613 patients in the 
hematological modifications were present in 62.3% of cases. Therefore, our results are similar to 
the data of some studies, whereas they differ substantially from others. It is difficult to explain 
the big difference for the hematopoietic system impairment, but we can suppose that the cause 
has been the recently instituted lupus—only 5 months in the reference group, while the hemato-
poietic system implication is a rare manifestation.
For obvious reasons, we referred our results to the data from other studies which reported to 
the presence of lupus diagnostic criteria: oral ulcerations, arthritis and arthralgia, serositis and 
renal lesions and we deduced that these attest in similar proportions to those appreciated by 
the prospective study of Harley (1989) [18]. Our data noted that the presence of photosensitiv-
ity in 65.1% of the patients and that of the malar erythema in 89.5 versus 36–41.5%, respec-
tively, which were discovered in the study of reference Harley (1989). The data referring to 
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hematological and immunological modifications and the antinuclear antibodies are similar 
to those appreciated throughout our study—64.3% cases. In all the patients with systemic 
lupus erythematosus, we remarked the presence of antinuclear autoantibodies (ANA) and 
anti-double-stranded DNA (anti-dsDNA), at least one of these indexes was found positive in 
the patients included in the study. According to the criteria defined by the American College 
of Rheumatology (ACR), the diagnosis of systemic lupus erythematosus was established on 
the basis of 4 or more criteria from the 11 criteria stated by the ACR, characteristics that were 
found simultaneously or successively in the patients investigated by our studies.
The study carried out analyzed the lupus patients with a hematological pathology, confirmed 
by a hematologist and the patients who did not manifest a pathology of the hematopoietic sys-
tem. Through clinical and paraclinical examination of the hematopoietic system of the patients 
with SLE from the selected group, we deduced that the disease can affect the hematopoietic 
system at any level, but has a predilection for these types of ailments: anemia, leukopenia, 
lymphopenia and thrombocytopenia.
In our study, the number of hematological syndromes has correlated positively with the high 
score of the SLAM index and the SLICC/ACR score, which suggested that more hematological 
manifestations could be associated with the high activity of the disease and can predispose to a 
further organ lesion. Nevertheless, some hematological events in SLE may only be the clinical 
presentation, persistent even at a low activity of the disease, without specific serological markers.
According to the investigational objectives, we analyzed the possible relations between the clini-
cal manifestation, the activity of the process and the organ lesion. The results of the research 
under this aspect have estimated that the evolution of the hematological manifestations depends 
on the activity of the lupus process. The impact of these on the organ lesion index and the quality 
of life was recorded. The index of organ lesion becomes higher with the display of hematologi-
cal events: anemia, leukopenia, lymphopenia and thrombocytopenia, which lower the patient’s 
quality of life significantly. Despite the frequent hematological manifestations in SLE, there are 
no specific clinical or paraclinical tests for the diagnosis of the implication of the hematopoietic 
system in SLE, and there are also no specific clinical or paraclinical tests for the diagnosis of the 
implication of the hematopoietic system in the disease evolution, all these imposing the neces-
sity of further research and the imperative demand for finding specific biomarkers for anemia.
With the purpose of establishing the importance of the reduction of erythropoietin level as a 
hypothetical biomarker that is associated with hematological disorders in lupus, particularly of 
the anemia of the chronic disease, we stratified the values depending on the obtained results. 
We examined the level of erythropoietin in 57 patients from the study group, in 3 of whom other 
types of anemia were found, 20 presenting iron-deficiency anemia of different degrees and 34 
patients had the anemia of the chronic disease. Continuing the analysis of the presented data, 
we discovered that in 43 patients the level of the researched index was subnormal—between 
1.12 and 3.22 μIU/ml. In 20 patients, the level of erythropoietin was estimated as normal and 
the diagnosis emitted—iron-deficiency anemia. We overlapped our records with the results in 
recent literature and we affiliated towards the principle that the level of erythropoietin may be 
useful in detecting the anemia in lupus. According to the data of Schett (2010) [3], the low titer 
of erythropoietin correlates with the anemia of the chronic disease in lupus, and the data only 
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confirmed this statement. All of the findings support the opinion that these patients require a 
dynamic evaluation and monitoring.
Calculations for the total doses of corticosteroids, also named cumulative dose, preoccupied 
us into relating it to the involvement of the hematopoietic system in the lupus process. The 
cumulative dose of corticosteroids was calculated according to the prednisolone dose admin-
istered orally throughout the disease, also including the pulse therapy. The cumulative dose, 
as is known, not only increases during the disease but also includes the pulse therapies which 
imply the administration of high doses of corticosteroids—1500 to 3000 mg (1.5–3.0 g) in a 
single cure or the programmed pulse therapy with a dose of 500 mg monthly. We divided 
the patients according to the quantity of corticosteroids administered and we considered the 
quantity below 5 g as a low dose, between 5 and 10 g as a medium dose and higher than 10 g as 
a high dose [11]. After the summary dose of corticosteroids, our patients accumulated mostly 
medium and high doses of corticosteroids—above 5 g. We did not detect a correlation of the 
doses of corticosteroids with the disorders of the hematopoietic system in the group of study.
According to the outlined objectives, we were motivated to analyze the damage to the 
hematopoietic system in accordance with the criteria for SLE elaborated by ACR (1999). The 
analysis of the results obtained shows a large and diverse specter of hematopoietic system 
implications in SLE. Of 86 patients examined in the study, the hematopoietic system impli-
cation and more precisely anemia were present in 59 (68.6%) patients. At the same time, the 
same patient may develop one or more hematological syndromes. Our data correspond to the 
data of the recent scientific methods dedicated to the assessment of the anemia in the context 
of lupus, including those reported by the cohort study carried out on 345 patients under the 
supervision of Voulgares and Kokori (2000) [23], which reported the clinical incidence of 
hematological manifestations in 38.4% of the patients.
From this study of reference, we ascertained that the most frequent hematological syndromes 
were the anemia of chronic disease—37.1% cases (39.5% in the patients examined by us), iron-
deficiency anemia—35.6% (versus 23.2% in our study), followed by autoimmune hemolytic 
anemia— 14.4% and other types of anemia—12.9% cases. According to these results we observe 
similarities between the frequency of the hematological syndromes detected in the patients 
from the study of reference and those enrolled in our study.
Therefore, the diversity of hematopoietic system damage reveals the indubitable value of 
applying the criteria developed by ACR (1999) for evaluating the patients with SLE.
Continuing the research on this subject, we insisted on the thorough approach of anemia as 
a form of hematopoietic system affliction in SLE. Anemia and other hematological disorders, 
such as leukopenia, lymphopenia and thrombocytopenia, are still a challenge for the diagnos-
ticians for reasons which include the fact that they could be either a direct manifestation of 
SLE or a secondary response to a chronic disease that affects the quality of life.
We tried to assess the indexes important for SLE in the patients without anemia tied to lupus 
and in those with the anemia of chronic disease. From the data reported before, it can be 
derived that the average age of onset in the patients without anemia was 34.73 years, whereas 
in the patients with anemia of chronic disease was 37.2 years. The patients with anemia of the 
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chronic disease also had been sick for a longer period of time—123.4 months compared to 
those without anemia—80.6 months. It has been determined that the accentuation of anemia 
happens during the disease. According to the activity of the disease appreciated through the 
SLAM index, it was established that the patients with anemia of chronic disease had the high-
est activity of the disease—22.6 points, whereas those without hematological manifestations 
showed a moderate activity—15.8 points. The index of organ lesion: SLICC was highest in 
patients with anemia of chronic disease showing values of 1.6 points qualified as an index of 
moderate organ lesion compared to the first group where the SLICC index was 0.5 points. Our 
data correspond to those affirmed in a study of reference, Vila (2009) [23] which reveals that 
anemia and other hematological syndromes occur on the background of active SLE and are 
associated with a longer age of the disease as well as the organ lesions are more emphasized.
According to the outlined objectives, we evaluated the parameters regarding the patient’s quality 
of life using the SF-36 score. The SF-36 accumulated values were 61 points in the patients without 
anemia and 41 points in the patients with moderate and severe depression; this being interpreted 
as a sign of a significantly reduced quality of life. An important study of reference carried out 
by Stoll (2009) [13] was dedicated to evaluating the quality of life of the patients with SLE and 
anemia. This study reveals a suggestive detail such as the fact that the routine assessment of the 
quality of life of the patients with SLE may facilitate the early detection of anemia.
Of course, we were also tempted to analyze the predictors of a reserved prognosis for the 
patients with SLE who during the disease develop a large variety of hematological syndromes 
that have an impact on the quality of life. After the analysis of our own data, we cataloged as 
such the manifestations of renal lesion, thrombocytopenia and a high level of anticardiolipin 
(aCL) antibodies presented in the patients with SLE and their role in inducing or associating 
hematological syndromes.
The analysis of diverse clinical manifestations in the hematological lupus was necessary 
because the persisting clinical indexes may pass on into the class of risk factors. Despite the 
fact that the paraclinical signs are included in the diagnosis criteria, we analyzed the cases 
included in the study group by stages. The study carried out by us detected high titers of anti-
dsDNA in both groups but only in 6 (23.0%) of the patients without anemia and 56 (94.9%) in 
those with anemia. Given the fact that aCL (anticardiolipin antibodies) is an index associated 
with disorders of the hematopoietic system, the analysis of the level of aCL antibodies, Ig and 
IgM, in the two groups of patients with lupus was a priority. It is to be remarked that in both 
groups the patients had high levels of anticardiolipin (aCL) IgG antibodies, but in the group 
without hematological lesions, their frequency was 22.2%, whereas in the patients with hema-
tological lupus it was 28.8% (p > 0.05). Continuing the examinations under this aspect, we 
detected anticardiolipin (aCL) IgM antibodies in 1 (3.7%) patient who did not develop anemia 
and in 4 (6.8%) patients who manifested anemia; the data obtained in our study being similar 
to those in a retrospective longitudinal study carried out by Pasero (2009) [14].
The antiphospholipid syndrome was present both in the patients without hematological 
disorders—8 (29.6%) cases and in those with hematological disorders—in 15 (25.4%) cases. 
Besides, the data obtained in our study coincide with those stipulated in the research carried 
out globally, according to which the association of the antiphospholipid syndrome is most 
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frequently reported in relation to the pattern of hematological events. According to the data 
that analyze the presence of livedo reticularis in the patients without anemia, we discovered 4 
(25.9%) of such cases, and in those with anemia this characteristic of the disease was signaled 
in 21 (35.6%) of the cases. Thereby, we conclude that the presence of livedo reticularis in the 
study carried out by us was associated to hematological manifestations and may be consid-
ered a factor that implies the risk of hematopoietic system affliction in the patients with lupus. 
Recent investigations report the presence of Raynaud syndrome as a specific risk factor for the 
development of anemia [18], but according to our data, the Raynaud syndrome was a rarely 
assessed phenomenon—in 1 (3.7%) patient without anemia and in 4 (6.8%) of those who did 
not develop anemia.
We intended to use valid instruments for the assessment of the quality of life in the patients 
with SLE. For this purpose, we applied the SF-36 questionnaire in its short version (short 
form-36). SF-36 is a brief way of testing but in the special literature there are also other sets of 
indexes used for reflecting the quality of life such as SF-20. According to the literature data, the 
SF-36 questionnaire possesses the capacity to evaluate the patients with lupus exhaustively—
a quality for which we preferred it in evaluating the impact of the hematopoietic system afflic-
tion on the quality of life of the lupus patients. The low quality of life of these people both by 
the mental health and the physical health, predominantly the physical one conditioned by the 
hematopoietic system afflictions in 35.6% of the cases. We compared our results with the data 
presented by Harley and Urowitz (2010) [22, 27], which indicate both the implication of the 
mental component and the physical one in determining the quality of life of the patients with 
hematopoietic dysfunctions on the background of lupus.
The data obtained by us after carrying out the study detected similar results with those reported 
by Harley (1989) [22], especially the ones referring to the vitality domain, physical function, 
general health and pain, but there were differences regarding affectivity and social function.
We analyzed comparatively the patients with anemia by means of the disease activity index, 
the organ lesion index and the impact of these on the quality of life. Our results were similar 
to those obtained in the study done in parallel with ours and recently emitted by other teams 
of researchers in the world [23], who confirmed that the quality of life index is inversely 
proportional to the activity of the disease and the organ lesion index for the patients with 
anemia.
Another study of reference carried out by Nossent and Locatelli (2004) [7] was dedicated to 
the interrelations of different dimensions and subscales of the generic questionnaire SF-36. 
Both our data and those from the study of reference denote the prevalence of low scores 
(<50 points) among the patients with SLE. In contrast to our data, the patients enrolled in 
the study by Moitinho (2011) [11] accumulated even higher scores—between 81-0 and even 
91-100, which were not observed among our patients. Thus, the data provided by the SF-36 
questionnaire attest the impact of the hematopoietic system dysfunctions in SLE on the qual-
ity of life, most of all through the development of major hematologic syndromes, by affecting 
all the criteria which characterize it. The low scores among the patients without hematological 
afflictions invoke that the chronic disease itself implies an important role in the patient’s life, 
the patient being often forced to review some aspects of their daily life, including some in 
regard to social relations and professional preoccupations.
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Even if it is insistently approached in several scientific centers, recognizing the hematological 
manifestations in the early stages of lupus still remains a challenge for the clinicians. Correctly 
attributing the hematological syndromes to those caused by the primary disease or to those 
that present as a reaction to suffering from a chronic and incurable disease or to the adverse 
reactions to medication or to some metabolic dysfunctions still remains a diagnostic dilemma 
[5, 13]. Because the physiopathology of these clinical manifestations is not fully elucidated, 
they cannot be attributed unequivocally to anemia.
An important moment and a problem with a difficult evolution are the subclinical manifesta-
tions of the hematopoietic system implication in SLE, which require an early identification 
and a gradual therapeutic intervention in order to improve upon the further disabilities of the 
patients. In this connection, the lack of a consensus in regard to the application of different 
hematological tests with a different potential of sensibility makes its mark. In the absence of a 
diagnostic standard and potential specific biomarkers for the hematologic affliction, various 
serological explorations and laboratory investigations are used to support the clinical diagno-
sis. The results of our study confirm this situation.
Our data correspond to those reported by Bertoli et al. LUMINA LI (2007) [20] and reveal 
that anemia is strictly associated with the activity of the disease and the organ lesion index 
both at the disease onset and during its evolution; this association being even closer than that 
with the anti-dsDNA antibodies. Moreover, anemia is associated with several clinical mani-
festations including, but not only, those that reflect a more severe disease such as the neuro-
psychiatric or renal implication. Ideally, the biomarkers have to be standardized and vastly 
applied especially when the hematocrit assessment is an easy and accessible test and can be 
considered a cheap indicator of the disease evolution, which allows the clinicians to anticipate 
the intermediary and long-term consequences of the lupus infection [22].
In our study, the relevance of anemia (independently of its cause) was estimated as being both 
a short-term prognostic factor (the activity of the disease) and a long-term (lesion index) prog-
nostic factor for the evolution of the disease. The estimated data in the lupus patients with 
anemia corresponded to those reported in the special literature and invoked the necessity of the 
improvement of early exploration, including through raising the awareness of the rheumatolo-
gists and the cooperation with the general practitioner, the hematologists, etc., who could advis-
edly get involved in the early detection of hematological dysfunctions, because through their 
improvement with specific methods, it is possible to maintain a long-term good quality of life.
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